In its July 24, 2010 edition (click here for full article), THE WALL STREET JOURNAL reported that NPC disease has been selected as one of only three diseases initially selected for a new program at the National Institutes of Health called Therapeutics for Rare and Neglected Diseases or TRND.  Due to the initial success of SOAR-NPC, TRND will be providing SOAR-NPC with a 5th principal investigator, a second clinical researcher for drug trials and 2 project managers with pharmaceutical industry experience to help guide the SOAR-NPC team toward its goal of a drug cocktail for NPC. Priceless!